December 15th 2017
OXFORD, UK, October 28th, 2016
PharmaVentures is pleased to announce that it acted as adviser to IDT Australia Limited for the successful divestment of CMAX, a dedicated clinical trials business, to the Japanese healthcare company I'rom Group Co. Ltd. for a minimum AUD 14,000,000.
OXFORD, UK, July 27st, 2016
PharmaVentures is pleased to announce that it acted as an adviser to the Baylor Scott & White Research Institute in connection with the creation of Denceptor Therapeutics Limited.
OXFORD, UK, July 21st, 2016
PharmaVentures is pleased to announce that today it has launched a new FCA regulated firm, Pharmaventures Capital Ltd which will carry out all future FCA regulated corporate finance related mandates.
The new firm, which is 100% owned by PharmaVentures, will be able to expand our client offering to include: publice transactions; certain transactions involving listed companies; and fund raising.
OXFORD, UK, March 22nd, 2016
PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. (To read the admission document, download the PDF)
OXFORD, UK, February 4th, 2016
PharmaVentures is pleased to announce that it acted as an advisor to Transgene on the sale of its biopharmaceutical manufacturing unit in Strasbourg, France, to the US company Advanced Bioscience Laboratories (ABL), Inc.
Transgene (Euronext: TNG), a member of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases.
Oxford, UK, 17th December, 2015:
PharmaVentures is pleased to announce that it acted as advisor to Stericool on its sale to Sweden’s Getinge Group, a global leader in infection control and contamination prevention solutions.
Oxford, UK, 16th September, 2015:
PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR).
OXFORD, UK, September 4th, 2015
PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in New Zealand for an undisclosed sum. The deal, completed on 1st September, includes an option for additional territories.
OXFORD, UK, June 30th, 2015
PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular imaging and analysis.
This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures' clients.